ArticleCytotechnology2025
EP300/CREBBP induces osteogenic differentiation of valve interstitial cells by promoting the SPP1 expression in calcific aortic valve disease.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secreted phosphoprotein 1 (SPP1) has been identified as a driver of fibrosis and inflammation, while its contribution to calcific aortic valve disease (CAVD) has not been clarified. In this research, we explored the possible role of SPP1 and the underlying molecular mechanism in CAVD. C57BL/6J mice were subjected to a high-fat diet (HFD), and human valve interstitial cells (VICs) were induced with the osteogenic medium (OM) for modeling. SPP1 was highly expressed in the human calcific aortic valve and VICs induced with OM, and its transcription was regulated by EP300/CREBBP. Knockdown of SPP1 inhibited the osteogenic differentiation of VICs, and overexpression of SPP1 reversed the repressive effect of EP300/CREBBP inhibitor on the osteogenic differentiation of VICs. EP300/CREBBP inhibitor ameliorated the aortic valve thickening and calcification in mice induced with HFD, and combined overexpression of SPP1 reversed the effect. In conclusion, the present findings suggest that EP300/CREBBP is dependent on SPP1 to induce osteogenic differentiation of VICs, thereby promoting the development of CAVD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.